27 September 2024 Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
The US Food and Drug Administration (FDA) on Friday approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. 28 September 2024
Shares of German pharma major Bayer were up 4.6% at 30.45 euros after it released positive early trial results for its Parkinson’s disease candidate. 27 September 2024
Shionogi said today that it has submitted a New Drug Application (NDA) in Japan for zuranolone, a treatment in development for major depressive disorder (MDD). 27 September 2024
CNS specialist Lundbeck has announced data from the TALISMAN natural history study, as well as additional data from the AMULET trial, of amlenetug, in multiple system atrophy (MSA) at the International Congress of Parkinson's Disease and Movement disorders in Philadelphia, USA. 27 September 2024
Repair Biotechnologies, a company developing therapies to reverse atherosclerotic plaque, has entered into a collaboration with Genevant Sciences, a specialist in nucleic acid delivery technology. 27 September 2024
China’s National Medical Products Administration (NMPA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). 27 September 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
US virology and immunology company Enanta Pharmaceuticals has given further weight to its claims to have the leading portfolio of potent respiratory syncytial virus (RSV) replication inhibitors 27 September 2024
Sage Therapeutics has announced that Biogen has terminated its partnership on the SAGE-324 program, following the recent failure of the drug in a Phase II study for the treatment of essential tremor. 27 September 2024
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a move which could affect blockbuster products such as Bristol Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab). 27 September 2024
The US Food and Drug Administration yesterday approved pharma major Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector. 27 September 2024
US drugmaker AbbVie has announced positive topline results from its pivotal Phase III TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. 26 September 2024
Evaxion Biotech has entered into an option and license agreement with MSD (tradename of Merck & Co outside of the USA and Canada), for two pre-clinical vaccine candidates. 26 September 2024
Danish CNS specialist Lundbeck and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. 26 September 2024
“In an increasingly globalized world, the exchange of knowledge is crucial for the pharmaceutical industry,” said Nelson Mussolini, Sindusfarma’s chairman. 23 July 2021
The European Commission has short-listed 11 new projects worth 120 million euros ($140 million) from Horizon Europe, the biggest European research and innovation program (2021-2027), for supporting and enabling urgent research into the coronavirus and its variants. 23 July 2021
Dutch biotech firm Synaffix today announced the signing of a license and option agreement with ProfoundBio, an emerging oncology biotherapeutics company headquartered in China. 22 July 2021
The USA continues to wrestle with the legacy of an epidemic of opioid abuse, believed to have cost the lives of over half a million people through overdose. In this episode, we talk to Mesoblast CEO Silviu Itescu about the a stem cell-based alternative currently subject to advanced regulatory discussions. 22 July 2021
The US Food and Drug Administration approved Keytruda (pembrolizumab) from Merck & Co in combination with Japanese drugmaker Eisai’s Lenvima (lenvatinib) for patients with advanced endometrial carcinoma' 22 July 2021
Pfizer and BioNTech have agreed for The Biovac Institute, a South African biopharmaceutical company, to manufacture their COVID-19 vaccine for distribution within Africa. 22 July 2021
Swiss pharma giant Roche posted financial results this morning showing that first-half 2021 net profit rose 2% to 8.22 billion Swiss francs ($8.96 billion) and sales increased by 8% at constant exchange rates to a better-than expected 30.71 billion francs. 22 July 2021
Swedish biotech Calliditas Therapeutics and Germany’s STADA Arzneimittel have entered into a license agreement to register and commercialize a novel specialty drug candidate for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy (IgAN) in the European Economic Area (EEA) member states, Switzerland and the UK. 22 July 2021
US clinical-stage biotech Magenta Therapeutics’ shares closed down more than 9% at $8.07 on Wednesday, after the company revealed it has received a clinical hold letter from the US Food and Drug Administration related to its Investigational New Drug Application (IND) filed in June 2021 to initiate a Phase I/II clinical trial of MGTA-117 in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). 22 July 2021
The international medical humanitarian organization Médecins Sans Frontières (MSF) says that trial results in HIV-related cryptococcal meningitis with a Gilead Sciences drug further compel the company to improve access. 21 July 2021
Following a positive recommendation from the European Medicines Agency’s human medicines committee (CHMP) in May, the European Commission (EC) has granted marketing authorization of Skysona (elivaldogene autotemcel, Lenti-D), developed by US biotech bluebird bio. 21 July 2021
Venclexta (venetoclax), in combination with azacytidine, has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA) for previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the revised International prognostic scoring system (IPSS-R). 21 July 2021
National Health Service (NHS) patients in England are set to benefit from early access to potentially life-saving new medicines, including cutting-edge gene therapies, thanks to a new Innovative Medicines Fund and £680 million ($925 million) of ringfenced funding, the NHS chief executive has announced today. 21 July 2021
The US Food & Drug Administration approval of Bylvay (odevixibat), the first drug approved for the treatment of pruritus in all subtypes of progressive familial intrahepatic cholestasis (PFIC), developed by Boston, USA-based Albireo Pharma. 21 July 2021
Japan’s Eisai has outlined details of 11 presentations slated for the upcoming annual Alzheimer’s Association International Conference (AAIC), taking place from 26 July in Colorado, USA. 21 July 2021